ID   ROCK2_HUMAN             Reviewed;        1388 AA.
AC   O75116; Q53QZ0; Q53SJ7; Q9UQN5;
DT   24-MAY-2004, integrated into UniProtKB/Swiss-Prot.
DT   24-NOV-2009, sequence version 4.
DT   10-MAY-2017, entry version 176.
DE   RecName: Full=Rho-associated protein kinase 2;
DE            EC=2.7.11.1;
DE   AltName: Full=Rho kinase 2;
DE   AltName: Full=Rho-associated, coiled-coil-containing protein kinase 2;
DE   AltName: Full=Rho-associated, coiled-coil-containing protein kinase II;
DE            Short=ROCK-II;
DE   AltName: Full=p164 ROCK-2;
GN   Name=ROCK2; Synonyms=KIAA0619;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ASN-431.
RC   TISSUE=Brain;
RX   PubMed=9933571; DOI=10.1006/geno.1998.5344;
RA   Takahashi N., Tuiki H., Saya H., Kaibuchi K.;
RT   "Localization of the gene coding for ROCK II/Rho kinase on human
RT   chromosome 2p24.";
RL   Genomics 55:235-237(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ASN-431.
RC   TISSUE=Brain;
RX   PubMed=9734811; DOI=10.1093/dnares/5.3.169;
RA   Ishikawa K., Nagase T., Suyama M., Miyajima N., Tanaka A., Kotani H.,
RA   Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. X.
RT   The complete sequences of 100 new cDNA clones from brain which can
RT   code for large proteins in vitro.";
RL   DNA Res. 5:169-176(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [4]
RP   FUNCTION, AND INTERACTION WITH PPP1R12A.
RX   PubMed=10579722; DOI=10.1083/jcb.147.5.1023;
RA   Kawano Y., Fukata Y., Oshiro N., Amano M., Nakamura T., Ito M.,
RA   Matsumura F., Inagaki M., Kaibuchi K.;
RT   "Phosphorylation of myosin-binding subunit (MBS) of myosin phosphatase
RT   by Rho-kinase in vivo.";
RL   J. Cell Biol. 147:1023-1038(1999).
RN   [5]
RP   CLEAVAGE BY GRANZYME B, MUTAGENESIS OF ASP-1131, AND FUNCTION.
RX   PubMed=15699075; DOI=10.1084/jem.20031877;
RA   Sebbagh M., Hamelin J., Bertoglio J., Solary E., Breard J.;
RT   "Direct cleavage of ROCK II by granzyme B induces target cell membrane
RT   blebbing in a caspase-independent manner.";
RL   J. Exp. Med. 201:465-471(2005).
RN   [6]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH EP300.
RX   PubMed=16574662; DOI=10.1074/jbc.M510954200;
RA   Tanaka T., Nishimura D., Wu R.C., Amano M., Iso T., Kedes L.,
RA   Nishida H., Kaibuchi K., Hamamori Y.;
RT   "Nuclear Rho kinase, ROCK2, targets p300 acetyltransferase.";
RL   J. Biol. Chem. 281:15320-15329(2006).
RN   [7]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH NPM1.
RX   PubMed=17015463; DOI=10.1128/MCB.01383-06;
RA   Ma Z., Kanai M., Kawamura K., Kaibuchi K., Ye K., Fukasawa K.;
RT   "Interaction between ROCK II and nucleophosmin/B23 in the regulation
RT   of centrosome duplication.";
RL   Mol. Cell. Biol. 26:9016-9034(2006).
RN   [8]
RP   PHOSPHORYLATION AT TYR-722, AND DEPHOSPHORYLATION.
RX   PubMed=18559669; DOI=10.1083/jcb.200710187;
RA   Lee H.H., Chang Z.F.;
RT   "Regulation of RhoA-dependent ROCKII activation by Shp2.";
RL   J. Cell Biol. 181:999-1012(2008).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1137, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1137, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [11]
RP   FUNCTION, AND INTERACTION WITH PPP1R12A.
RX   PubMed=19131646; DOI=10.1161/CIRCRESAHA.108.188524;
RA   Wang Y., Zheng X.R., Riddick N., Bryden M., Baur W., Zhang X.,
RA   Surks H.K.;
RT   "ROCK isoform regulation of myosin phosphatase and contractility in
RT   vascular smooth muscle cells.";
RL   Circ. Res. 104:531-540(2009).
RN   [12]
RP   FUNCTION.
RX   PubMed=19997641; DOI=10.1371/journal.pone.0008190;
RA   Lock F.E., Hotchin N.A.;
RT   "Distinct roles for ROCK1 and ROCK2 in the regulation of keratinocyte
RT   differentiation.";
RL   PLoS ONE 4:E8190-E8190(2009).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1137, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [14]
RP   INTERACTION WITH CHORDC1.
RX   PubMed=20230755; DOI=10.1016/j.devcel.2009.12.020;
RA   Ferretti R., Palumbo V., Di Savino A., Velasco S., Sbroggio M.,
RA   Sportoletti P., Micale L., Turco E., Silengo L., Palumbo G.,
RA   Hirsch E., Teruya-Feldstein J., Bonaccorsi S., Pandolfi P.P.,
RA   Gatti M., Tarone G., Brancaccio M.;
RT   "Morgana/chp-1, a ROCK inhibitor involved in centrosome duplication
RT   and tumorigenesis.";
RL   Dev. Cell 18:486-495(2010).
RN   [15]
RP   PHOSPHORYLATION AT TYR-722.
RX   PubMed=20826462; DOI=10.1242/jcs.071555;
RA   Lee H.H., Tien S.C., Jou T.S., Chang Y.C., Jhong J.G., Chang Z.F.;
RT   "Src-dependent phosphorylation of ROCK participates in regulation of
RT   focal adhesion dynamics.";
RL   J. Cell Sci. 123:3368-3377(2010).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1137, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [18]
RP   FUNCTION, AND INTERACTION WITH BRCA2.
RX   PubMed=21084279; DOI=10.1158/0008-5472.CAN-10-0030;
RA   Wang H.F., Takenaka K., Nakanishi A., Miki Y.;
RT   "BRCA2 and nucleophosmin coregulate centrosome amplification and form
RT   a complex with the Rho effector kinase ROCK2.";
RL   Cancer Res. 71:68-77(2011).
RN   [19]
RP   FUNCTION, AND INTERACTION WITH SORL1.
RX   PubMed=21147781; DOI=10.1074/jbc.M110.167239;
RA   Herskowitz J.H., Seyfried N.T., Gearing M., Kahn R.A., Peng J.,
RA   Levey A.I., Lah J.J.;
RT   "Rho kinase II phosphorylation of the lipoprotein receptor LR11/SORLA
RT   alters amyloid-beta production.";
RL   J. Biol. Chem. 286:6117-6127(2011).
RN   [20]
RP   REVIEW.
RX   PubMed=12778124; DOI=10.1038/nrm1128;
RA   Riento K., Ridley A.J.;
RT   "Rocks: multifunctional kinases in cell behaviour.";
RL   Nat. Rev. Mol. Cell Biol. 4:446-456(2003).
RN   [21]
RP   REVIEW.
RX   PubMed=20803696; DOI=10.1002/cm.20472;
RA   Amano M., Nakayama M., Kaibuchi K.;
RT   "Rho-kinase/ROCK: A key regulator of the cytoskeleton and cell
RT   polarity.";
RL   Cytoskeleton 67:545-554(2010).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1137, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-1212; SER-1362 AND
RP   SER-1374, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [26]
RP   VARIANTS [LARGE SCALE ANALYSIS] ASN-431; VAL-601 AND PRO-1194.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Protein kinase which is a key regulator of actin
CC       cytoskeleton and cell polarity. Involved in regulation of smooth
CC       muscle contraction, actin cytoskeleton organization, stress fiber
CC       and focal adhesion formation, neurite retraction, cell adhesion
CC       and motility via phosphorylation of ADD1, BRCA2, CNN1, EZR,
CC       DPYSL2, EP300, MSN, MYL9/MLC2, NPM1, RDX, PPP1R12A and VIM.
CC       Phosphorylates SORL1 and IRF4. Acts as a negative regulator of
CC       VEGF-induced angiogenic endothelial cell activation. Positively
CC       regulates the activation of p42/MAPK1-p44/MAPK3 and of
CC       p90RSK/RPS6KA1 during myogenic differentiation. Plays an important
CC       role in the timely initiation of centrosome duplication. Inhibits
CC       keratinocyte terminal differentiation. May regulate closure of the
CC       eyelids and ventral body wall through organization of actomyosin
CC       bundles. Plays a critical role in the regulation of spine and
CC       synaptic properties in the hippocampus. Plays an important role in
CC       generating the circadian rhythm of the aortic myofilament Ca(2+)
CC       sensitivity and vascular contractility by modulating the myosin
CC       light chain phosphorylation. {ECO:0000269|PubMed:10579722,
CC       ECO:0000269|PubMed:15699075, ECO:0000269|PubMed:16574662,
CC       ECO:0000269|PubMed:17015463, ECO:0000269|PubMed:19131646,
CC       ECO:0000269|PubMed:19997641, ECO:0000269|PubMed:21084279,
CC       ECO:0000269|PubMed:21147781}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC   -!- ENZYME REGULATION: Activated by RHOA binding. Inhibited by Y-27632
CC       (By similarity). {ECO:0000250}.
CC   -!- SUBUNIT: Homodimer. Interacts with IRS1, RHOB and RHOC (By
CC       similarity). Interacts with RHOA (activated by GTP), PPP1R12A,
CC       CHORDC1, SORL1, EP300 and BRCA2. Interacts with NPM1 and this
CC       interaction enhances its activity. Interacts with RAF1 (By
CC       similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Cell membrane {ECO:0000250};
CC       Peripheral membrane protein {ECO:0000250}. Nucleus. Cytoplasm,
CC       cytoskeleton, microtubule organizing center, centrosome.
CC       Note=Cytoplasmic, and associated with actin microfilaments and the
CC       plasma membrane. {ECO:0000250}.
CC   -!- DOMAIN: An interaction between Thr-414 and Asp-48 is essential for
CC       kinase activity and dimerization. {ECO:0000250}.
CC   -!- PTM: Phosphorylation at Tyr-722 reduces its binding to RHOA and is
CC       crucial for focal adhesion dynamics. Dephosphorylation by PTPN11
CC       stimulates its RHOA binding activity.
CC       {ECO:0000269|PubMed:18559669, ECO:0000269|PubMed:20826462}.
CC   -!- PTM: Cleaved by granzyme B during apoptosis. This leads to
CC       constitutive activation of the kinase and membrane blebbing.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAX93049.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=BAA31594.2; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/ROCK2ID43474ch2p25.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; D87931; BAA75636.1; -; mRNA.
DR   EMBL; AB014519; BAA31594.2; ALT_INIT; mRNA.
DR   EMBL; AC018463; AAX93049.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AC099344; AAY14825.1; -; Genomic_DNA.
DR   CCDS; CCDS42654.1; -.
DR   RefSeq; NP_001308572.1; NM_001321643.1.
DR   RefSeq; NP_004841.2; NM_004850.4.
DR   UniGene; Hs.681743; -.
DR   PDB; 4L6Q; X-ray; 2.79 A; A/B=19-417.
DR   PDB; 4WOT; X-ray; 2.93 A; A/B/C/D=22-417.
DR   PDB; 5U7Q; X-ray; 3.15 A; A/B/C/D=23-417.
DR   PDB; 5U7R; X-ray; 3.33 A; A/B/C/D=23-417.
DR   PDBsum; 4L6Q; -.
DR   PDBsum; 4WOT; -.
DR   PDBsum; 5U7Q; -.
DR   PDBsum; 5U7R; -.
DR   ProteinModelPortal; O75116; -.
DR   SMR; O75116; -.
DR   BioGrid; 114860; 24.
DR   IntAct; O75116; 10.
DR   MINT; MINT-4299744; -.
DR   STRING; 9606.ENSP00000317985; -.
DR   BindingDB; O75116; -.
DR   ChEMBL; CHEMBL2973; -.
DR   DrugBank; DB08756; (R)-TRANS-4-(1-AMINOETHYL)-N-(4-PYRIDYL) CYCLOHEXANECARBOXAMIDE.
DR   GuidetoPHARMACOLOGY; 1504; -.
DR   iPTMnet; O75116; -.
DR   PhosphoSitePlus; O75116; -.
DR   SwissPalm; O75116; -.
DR   BioMuta; ROCK2; -.
DR   EPD; O75116; -.
DR   MaxQB; O75116; -.
DR   PaxDb; O75116; -.
DR   PeptideAtlas; O75116; -.
DR   PRIDE; O75116; -.
DR   Ensembl; ENST00000315872; ENSP00000317985; ENSG00000134318.
DR   GeneID; 9475; -.
DR   KEGG; hsa:9475; -.
DR   UCSC; uc002rbd.2; human.
DR   CTD; 9475; -.
DR   DisGeNET; 9475; -.
DR   GeneCards; ROCK2; -.
DR   H-InvDB; HIX0001828; -.
DR   HGNC; HGNC:10252; ROCK2.
DR   HPA; CAB008666; -.
DR   HPA; HPA007459; -.
DR   HPA; HPA044109; -.
DR   MIM; 604002; gene.
DR   neXtProt; NX_O75116; -.
DR   OpenTargets; ENSG00000134318; -.
DR   PharmGKB; PA34624; -.
DR   eggNOG; KOG0612; Eukaryota.
DR   eggNOG; ENOG410XR1Q; LUCA.
DR   GeneTree; ENSGT00760000118994; -.
DR   HOGENOM; HOG000017259; -.
DR   HOVERGEN; HBG053111; -.
DR   InParanoid; O75116; -.
DR   KO; K17388; -.
DR   OMA; PNQSIRR; -.
DR   OrthoDB; EOG091G0BOR; -.
DR   PhylomeDB; O75116; -.
DR   TreeFam; TF313551; -.
DR   Reactome; R-HSA-3928662; EPHB-mediated forward signaling.
DR   Reactome; R-HSA-3928663; EPHA-mediated growth cone collapse.
DR   Reactome; R-HSA-416482; G alpha (12/13) signalling events.
DR   Reactome; R-HSA-416572; Sema4D induced cell migration and growth-cone collapse.
DR   Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway.
DR   Reactome; R-HSA-5627117; RHO GTPases Activate ROCKs.
DR   SignaLink; O75116; -.
DR   SIGNOR; O75116; -.
DR   ChiTaRS; ROCK2; human.
DR   GenomeRNAi; 9475; -.
DR   PRO; PR:O75116; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   Bgee; ENSG00000134318; -.
DR   CleanEx; HS_ROCK2; -.
DR   ExpressionAtlas; O75116; baseline and differential.
DR   Genevisible; O75116; HS.
DR   GO; GO:0005813; C:centrosome; IDA:UniProtKB.
DR   GO; GO:0036464; C:cytoplasmic ribonucleoprotein granule; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0017048; F:Rho GTPase binding; IEA:InterPro.
DR   GO; GO:0072518; F:Rho-dependent protein serine/threonine kinase activity; IMP:UniProtKB.
DR   GO; GO:0003723; F:RNA binding; IDA:UniProtKB.
DR   GO; GO:0005198; F:structural molecule activity; NAS:ProtInc.
DR   GO; GO:0071394; P:cellular response to testosterone stimulus; IMP:UniProtKB.
DR   GO; GO:0051298; P:centrosome duplication; IMP:UniProtKB.
DR   GO; GO:0030866; P:cortical actin cytoskeleton organization; IMP:UniProtKB.
DR   GO; GO:0000910; P:cytokinesis; NAS:ProtInc.
DR   GO; GO:0048013; P:ephrin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0090002; P:establishment of protein localization to plasma membrane; IMP:UniProtKB.
DR   GO; GO:0007249; P:I-kappaB kinase/NF-kappaB signaling; IMP:UniProtKB.
DR   GO; GO:0016525; P:negative regulation of angiogenesis; IMP:UniProtKB.
DR   GO; GO:1903347; P:negative regulation of bicellular tight junction assembly; IGI:UniProtKB.
DR   GO; GO:0035509; P:negative regulation of myosin-light-chain-phosphatase activity; IMP:UniProtKB.
DR   GO; GO:0010825; P:positive regulation of centrosome duplication; IEA:InterPro.
DR   GO; GO:0010595; P:positive regulation of endothelial cell migration; IMP:UniProtKB.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:UniProtKB.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IMP:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0032956; P:regulation of actin cytoskeleton organization; TAS:UniProtKB.
DR   GO; GO:0030155; P:regulation of cell adhesion; TAS:UniProtKB.
DR   GO; GO:2000145; P:regulation of cell motility; TAS:UniProtKB.
DR   GO; GO:0042752; P:regulation of circadian rhythm; ISS:UniProtKB.
DR   GO; GO:2000114; P:regulation of establishment of cell polarity; TAS:UniProtKB.
DR   GO; GO:1903140; P:regulation of establishment of endothelial barrier; IMP:UniProtKB.
DR   GO; GO:0051893; P:regulation of focal adhesion assembly; TAS:UniProtKB.
DR   GO; GO:0045616; P:regulation of keratinocyte differentiation; IMP:UniProtKB.
DR   GO; GO:0051492; P:regulation of stress fiber assembly; TAS:UniProtKB.
DR   GO; GO:0007266; P:Rho protein signal transduction; IEA:InterPro.
DR   GO; GO:0048511; P:rhythmic process; IEA:UniProtKB-KW.
DR   GO; GO:0006939; P:smooth muscle contraction; TAS:UniProtKB.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0039694; P:viral RNA genome replication; IMP:ParkinsonsUK-UCL.
DR   CDD; cd00029; C1; 1.
DR   Gene3D; 2.30.29.30; -; 1.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR002219; PE/DAG-bd.
DR   InterPro; IPR011993; PH_dom-like.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR015008; Rho-bd_dom.
DR   InterPro; IPR020684; ROCK1/ROCK2.
DR   InterPro; IPR029878; ROCK2.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   PANTHER; PTHR22988:SF40; PTHR22988:SF40; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF08912; Rho_Binding; 1.
DR   PIRSF; PIRSF037568; Rho_kinase; 1.
DR   SMART; SM00109; C1; 1.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF50729; SSF50729; 2.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS50081; ZF_DAG_PE_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Biological rhythms; Cell membrane;
KW   Coiled coil; Complete proteome; Cytoplasm; Cytoskeleton; Kinase;
KW   Magnesium; Membrane; Metal-binding; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Polymorphism; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase; Zinc; Zinc-finger.
FT   CHAIN         1   1388       Rho-associated protein kinase 2.
FT                                /FTId=PRO_0000086625.
FT   DOMAIN       92    354       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN      357    425       AGC-kinase C-terminal.
FT   REPEAT      475    559       REM.
FT   DOMAIN     1150   1349       PH. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00145}.
FT   NP_BIND      98    106       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ZN_FING    1260   1315       Phorbol-ester/DAG-type.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00226}.
FT   REGION      363    784       Interaction with PPP1R12A.
FT   REGION      373    420       Interaction with NPM1.
FT                                {ECO:0000269|PubMed:17015463}.
FT   REGION      979   1047       RHOA binding. {ECO:0000250}.
FT   COILED      429   1024       {ECO:0000255}.
FT   COILED     1053   1131       {ECO:0000255}.
FT   ACT_SITE    214    214       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING     121    121       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   SITE       1131   1132       Cleavage; by granzyme B.
FT   MOD_RES     414    414       Phosphothreonine; by ROCK2.
FT                                {ECO:0000250}.
FT   MOD_RES     722    722       Phosphotyrosine; by SRC.
FT                                {ECO:0000269|PubMed:18559669,
FT                                ECO:0000269|PubMed:20826462}.
FT   MOD_RES    1137   1137       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692}.
FT   MOD_RES    1212   1212       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1362   1362       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1374   1374       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   VARIANT     431    431       T -> N (in dbSNP:rs2230774).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|PubMed:9734811,
FT                                ECO:0000269|PubMed:9933571}.
FT                                /FTId=VAR_041062.
FT   VARIANT     601    601       D -> V (in dbSNP:rs35768389).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041063.
FT   VARIANT    1083   1083       K -> M (in dbSNP:rs34945852).
FT                                /FTId=VAR_057110.
FT   VARIANT    1194   1194       S -> P (in a metastatic melanoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041064.
FT   MUTAGEN    1131   1131       D->A: Abolishes cleavage by granzyme B.
FT                                {ECO:0000269|PubMed:15699075}.
FT   CONFLICT     83     83       R -> K (in Ref. 1; BAA75636).
FT                                {ECO:0000305}.
FT   HELIX        29     35       {ECO:0000244|PDB:4L6Q}.
FT   HELIX        43     57       {ECO:0000244|PDB:4L6Q}.
FT   HELIX        60     63       {ECO:0000244|PDB:4L6Q}.
FT   HELIX        66     85       {ECO:0000244|PDB:4L6Q}.
FT   HELIX        89     91       {ECO:0000244|PDB:4L6Q}.
FT   STRAND       92    100       {ECO:0000244|PDB:4L6Q}.
FT   STRAND      102    111       {ECO:0000244|PDB:4L6Q}.
FT   TURN        112    114       {ECO:0000244|PDB:4L6Q}.
FT   STRAND      117    124       {ECO:0000244|PDB:4L6Q}.
FT   HELIX       125    130       {ECO:0000244|PDB:4L6Q}.
FT   HELIX       138    146       {ECO:0000244|PDB:4L6Q}.
FT   STRAND      155    160       {ECO:0000244|PDB:4L6Q}.
FT   STRAND      162    169       {ECO:0000244|PDB:4L6Q}.
FT   HELIX       177    183       {ECO:0000244|PDB:4L6Q}.
FT   HELIX       188    207       {ECO:0000244|PDB:4L6Q}.
FT   HELIX       217    219       {ECO:0000244|PDB:4L6Q}.
FT   STRAND      220    222       {ECO:0000244|PDB:4L6Q}.
FT   STRAND      228    230       {ECO:0000244|PDB:4L6Q}.
FT   STRAND      241    246       {ECO:0000244|PDB:4L6Q}.
FT   HELIX       254    256       {ECO:0000244|PDB:4L6Q}.
FT   HELIX       259    264       {ECO:0000244|PDB:4L6Q}.
FT   STRAND      270    272       {ECO:0000244|PDB:4L6Q}.
FT   HELIX       274    289       {ECO:0000244|PDB:4L6Q}.
FT   HELIX       299    307       {ECO:0000244|PDB:4L6Q}.
FT   HELIX       309    312       {ECO:0000244|PDB:4L6Q}.
FT   HELIX       323    332       {ECO:0000244|PDB:4L6Q}.
FT   HELIX       336    338       {ECO:0000244|PDB:4L6Q}.
FT   TURN        340    343       {ECO:0000244|PDB:4L6Q}.
FT   HELIX       346    349       {ECO:0000244|PDB:4L6Q}.
FT   HELIX       352    354       {ECO:0000244|PDB:4L6Q}.
FT   TURN        361    363       {ECO:0000244|PDB:4L6Q}.
FT   HELIX       364    366       {ECO:0000244|PDB:4L6Q}.
FT   HELIX       408    410       {ECO:0000244|PDB:4L6Q}.
SQ   SEQUENCE   1388 AA;  160900 MW;  876240F410C2487E CRC64;
     MSRPPPTGKM PGAPETAPGD GAGASRQRKL EALIRDPRSP INVESLLDGL NSLVLDLDFP
     ALRKNKNIDN FLNRYEKIVK KIRGLQMKAE DYDVVKVIGR GAFGEVQLVR HKASQKVYAM
     KLLSKFEMIK RSDSAFFWEE RDIMAFANSP WVVQLFYAFQ DDRYLYMVME YMPGGDLVNL
     MSNYDVPEKW AKFYTAEVVL ALDAIHSMGL IHRDVKPDNM LLDKHGHLKL ADFGTCMKMD
     ETGMVHCDTA VGTPDYISPE VLKSQGGDGF YGRECDWWSV GVFLYEMLVG DTPFYADSLV
     GTYSKIMDHK NSLCFPEDAE ISKHAKNLIC AFLTDREVRL GRNGVEEIRQ HPFFKNDQWH
     WDNIRETAAP VVPELSSDID SSNFDDIEDD KGDVETFPIP KAFVGNQLPF IGFTYYRENL
     LLSDSPSCRE TDSIQSRKNE ESQEIQKKLY TLEEHLSNEM QAKEELEQKC KSVNTRLEKT
     AKELEEEITL RKSVESALRQ LEREKALLQH KNAEYQRKAD HEADKKRNLE NDVNSLKDQL
     EDLKKRNQNS QISTEKVNQL QRQLDETNAL LRTESDTAAR LRKTQAESSK QIQQLESNNR
     DLQDKNCLLE TAKLKLEKEF INLQSALESE RRDRTHGSEI INDLQGRICG LEEDLKNGKI
     LLAKVELEKR QLQERFTDLE KEKSNMEIDM TYQLKVIQQS LEQEEAEHKA TKARLADKNK
     IYESIEEAKS EAMKEMEKKL LEERTLKQKV ENLLLEAEKR CSLLDCDLKQ SQQKINELLK
     QKDVLNEDVR NLTLKIEQET QKRCLTQNDL KMQTQQVNTL KMSEKQLKQE NNHLMEMKMN
     LEKQNAELRK ERQDADGQMK ELQDQLEAEQ YFSTLYKTQV RELKEECEEK TKLGKELQQK
     KQELQDERDS LAAQLEITLT KADSEQLARS IAEEQYSDLE KEKIMKELEI KEMMARHKQE
     LTEKDATIAS LEETNRTLTS DVANLANEKE ELNNKLKDVQ EQLSRLKDEE ISAAAIKAQF
     EKQLLTERTL KTQAVNKLAE IMNRKEPVKR GNDTDVRRKE KENRKLHMEL KSEREKLTQQ
     MIKYQKELNE MQAQIAEESQ IRIELQMTLD SKDSDIEQLR SQLQALHIGL DSSSIGSGPG
     DAEADDGFPE SRLEGWLSLP VRNNTKKFGW VKKYVIVSSK KILFYDSEQD KEQSNPYMVL
     DIDKLFHVRP VTQTDVYRAD AKEIPRIFQI LYANEGESKK EQEFPVEPVG EKSNYICHKG
     HEFIPTLYHF PTNCEACMKP LWHMFKPPPA LECRRCHIKC HKDHMDKKEE IIAPCKVYYD
     ISTAKNLLLL ANSTEEQQKW VSRLVKKIPK KPPAPDPFAR SSPRTSMKIQ QNQSIRRPSR
     QLAPNKPS
//
